Clinical significance of thyroid transcription factor-1 in advanced lung adenocarcinoma under epidermal growth factor receptor tyrosine kinase inhibitor treatment

Chest

Volumn 141, Issue 2, 2012, Pages 420-428

  Chung, Kuei Pin ^a   Huang, Yen Tsung ^c   Chang, Yih Leong ^a   Yu, Chong Jen ^a   Yang, Chih Hsin ^b   Chang, Yeun Chung ^a   Shih, Jin Yuan ^a   Yang, Pan Chyr ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; THYROID TRANSCRIPTION FACTOR 1;

ADULT; ADVANCED CANCER; AGED; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG RESPONSE; EGFR GENE; FEMALE; GENE; HUMAN; HUMAN TISSUE; KRAS GENE; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; TAIWAN; THORAX RADIOGRAPHY;

EID: 84863069261     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.10-3149     Document Type: Article

References (39)

1. Maeda Y, Davé V, Whitsett JA. Transcriptional control of lung morphogenesis. Physiol Rev. 2007;87(1):219-244. (Pubitemid 46207714)
2. Chang YL, Lee YC, Liao WY, Wu CT. The utility and limitation of thyroid transcription factor-1 protein in primary and metastatic pulmonary neoplasms. Lung Cancer. 2004;44(2):149-157.
3. Lau SK, Luthringer DJ, Eisen RN. Thyroid transcription factor-1: a review. Appl Immunohistochem Mol Morphol.2002;10(2):97-102. (Pubitemid 34553163)
4. Yatabe Y, Mitsudomi T, Takahashi T. TTF-1 expression in pulmonary adenocarcinomas. Am J Surg Pathol. 2002;26(6):767-773. (Pubitemid 34546942)
5. Barlési F, Pinot D, Legoffic A, et al. Positive thyroid transcription factor 1 staining strongly correlates with survival of patients with adenocarcinoma of the lung. Br J Cancer.2005;93(4):450-452. (Pubitemid 43080019)
6. Anagnostou VK, Syrigos KN, Bepler G, Homer RJ, Rimm DL. Thyroid transcription factor 1 is an independent prognostic factor for patients with stage I lung adenocarcinoma. J Clin Oncol. 2009;27(2):271-278.
7. Barletta JA, Perner S, Iafrate AJ, et al. Clinical significance of TTF-1 protein expression and TTF-1 gene amplification in lung adenocarcinoma. J Cell Mol Med. 2009;13(8B):1977-1986.
8. Takeuchi T, Tomida S, Yatabe Y, et al. Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors. J Clin Oncol. 2006; 24(11):1679-1688. (Pubitemid 46622139)
9. Yatabe Y, Kosaka T, Takahashi T, Mitsudomi T. EGFR mutation is specific for terminal respiratory unit type adenocarcinoma. Am J Surg Pathol. 2005;29(5):633-639. (Pubitemid 40577873)
10. Tapia C, Savic S, Bihl M, et al. EGFR mutation analysis in non-small-cell lung cancer : experience from routine diagnostics [in German]. Pathologe. 2009;30(5):384-392.
11. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med.2004;350(21):2129-2139. (Pubitemid 38637993)
12. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005;2(3):e73.
13. Shih JY, Gow CH, Yang PC. EGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer. N Engl J Med. 2005;353(2):207-208. (Pubitemid 41058355)
14. Yang CH, Yu CJ, Shih JY, et al. Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy. J Clin Oncol. 2008;26(16):2745-2753.
15. Wu JY, Wu SG, Yang CH, et al. Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response. Clin Cancer Res.2008;14(15):4877-4882.
16. Mitsudomi T, Kosaka T, Endoh H, et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol.2005;23(11):2513-2520. (Pubitemid 47050841)
17. Takano T, Fukui T, Ohe Y, et al. EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan. J Clin Oncol.2008;26(34):5589-5595.
18. Mitsudomi T, Morita S, Yatabe Y, et al West Japan Oncology Group. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010;11(2):121-128.
19. Maemondo M, Inoue A, Kobayashi K, et al North-East Japan Study Group. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362(25):2380-2388.
20. Travis WD. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Oxford, England: Oxford University Press; 2004.
21. Greene FL. AJCC Cancer Staging Manual. New York, NY: Springer; 2002.
22. Shih JY, Gow CH, Yu CJ, et al. Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer. Int J Cancer.2006;118(4):963-969. (Pubitemid 43157672)
23. Wu JY, Yu CJ, Yang CH, et al. First- or second-line therapy with gefitinib produces equal survival in non-small cell lung cancer. Am J Respir Crit Care Med. 2008;178(8):847-853.
24. Wu SG, Gow CH, Yu CJ, et al. Frequent epidermal growth factor receptor gene mutations in malignant pleural effusion of lung adenocarcinoma. Eur Respir J. 2008;32(4):924-930.
25. Wu JY, Yang CH, Hsu YC, et al. Use of cetuximab after failure of gefitinib in patients with advanced non-small-cell lung cancer. Clin Lung Cancer. 2010;11(4):257-263.
26. Travis WD, Brambilla E, Noguchi M, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol.2011;6(2):244-285.
27. Saito RA, Watabe T, Horiguchi K, et al. Thyroid transcription factor-1 inhibits transforming growth factor-beta-mediated epithelial-to-mesenchymal transition in lung adenocarcinoma cells. Cancer Res. 2009;69(7):2783-2791.
28. Riely GJ, Marks J, Pao W. KRAS mutations in non-small cell lung cancer. Proc Am Thorac Soc. 2009;6(2):201-205.
29. Yauch RL, Januario T, Eberhard DA, et al. Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin Cancer Res. 2005;11(24 pt 1):8686-8698. (Pubitemid 43005918)
30. Tan D, Li Q, Deeb G, et al. Thyroid transcription factor-1 expression prevalence and its clinical implications in non-small cell lung cancer: a high-throughput tissue microarray and immunohistochemistry study. Hum Pathol. 2003;34(6):597-604. (Pubitemid 36750372)
31. Tanaka H, Yanagisawa K, Shinjo K, et al. Lineage-specific dependency of lung adenocarcinomas on the lung development regulator TTF-1. Cancer Res. 2007;67(13):6007-6011. (Pubitemid 47037477)
32. Kwei KA, Kim YH, Girard L, et al. Genomic profiling identifies TITF1 as a lineage-specific oncogene amplified in lung cancer. Oncogene. 2008;27(25):3635-3640. (Pubitemid 351793793)
33. Weir BA, Woo MS, Getz G, et al. Characterizing the cancer genome in lung adenocarcinoma. Nature. 2007;450(7171):893-898. (Pubitemid 350231325)
34. Rosell R, Moran T, Queralt C, et al Spanish Lung Cancer Group. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009; 361(10): 958- 967.
35. Shih JY, Tsai MF, Chang TH, et al. Transcription repressor slug promotes carcinoma invasion and predicts outcome of patients with lung adenocarcinoma. Clin Cancer Res. 2005;11(22):8070-8078.
36. Yanagawa J, Walser TC, Zhu LX, et al. Snail promotes CXCR2 ligand-dependent tumor progression in non-small cell lung carcinoma. Clin Cancer Res. 2009;15(22):6820-6829.
37. Thomson S, Buck E, Petti F, et al. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res.2005;65(20):9455-9462. (Pubitemid 41508014)
38. Chang TH, Tsai MF, Su KY, et al. Slug confers resistance to the epidermal growth factor receptor tyrosine kinase inhibitor. Am J Respir Crit Care Med. 2011;183(8):1071-1079.
39. Winslow MM, Dayton TL, Verhaak RG, et al. Suppression of lung adenocarcinoma progression by Nkx2-1. Nature.2011;473(7345):101-104.